Global Overactive Bladder (OAB) Treatment Market - Analysis By Medication, By Therapy, By Region, By Country (2019 Edition): Opportunities and Forecast (2019-2024) - By Region (N. America, Europe, APAC, ROW), By Country (US, Canada, Mexico, France, Germany, Italy, Spain, China, India, Japan) 2022-2030
3 Dec 2021
Healthcare & Pharmaceuticals
Impact Analysis on the Growth of Market
Activating Probable Propositions Amidst COVID-19 Crisis
With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More
The Research Report is Updated with 2020 Base Year, 2021 Estimated year and Forecast till 2030 with Market Insights.
With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2020 as base year, 2021 as estimated year and forecast to 2030. This will have market drivers, recovery rate in the market, insights and competitive analysis.
" The global overactive bladder market is estimated to be valued at ~USD 6 billion by the end of 2021 and is projected to expand at a CAGR of 3% over the period 2022-2030. Emerging technologies and drug developments are driving the overactive bladder treatment market, driven by rising healthcare and infrastructure costs and an increasing number of elderly.
Additionally, the advent of combination therapies and increasing drug approvals will stimulate the overactive bladder treatment market. Also, the continuous therapeutic advancement in the pharmaceutical industry is driving the demand for overactive bladder, which is expected to drive the growth of the global overactive bladder treatment market.
Oxybutynin is valued by pharmacists driving global market growth primarily due to its affordability, superior efficacy and low adherence to OAB treatment. Botox treatment accelerates healing because Botox is inexpensive even in the hospital under general anesthesia.
However, it can also be done under local anesthesia. Also, Botox is a step and does not require a foreign body implant. Botox treatment is an acceptable treatment for doctors and requires less additional skill than cystoscopy. Botox is considered safe and the only side effect is that 6% of cases require a temporary catheter and 18% of cases require urological care. Depending on the type of treatment, NMS treatment leads to higher growth and should not replace leakage efficiency due to higher drying rates, higher zero pillow use, and better frequency/urgency. Also, NMS treatment is more comprehensive than Botox treatment and is a restorative treatment that restores the patients function. More complications (about 20%) occur with NMS. This usually includes unwanted irritation and pain at the implant site.
REPORT SCOPE :
Global Overactive Bladder Treatment Market (ACTUAL PERIOD: 2014-2021, FORECAST PERIOD: 2022- 2030) • Overactive Bladder Treatment Market Forecast by Size, Growth, Price, etc. of Mirabegron • Treatment Analysis: Botox, NMS Therapy, PTNS.
REGIONAL ANALYSIS :
North America, Asia Pacific, Europe and the rest of the world (ACTUAL PERIOD: 2014-2021, FORECAST PERIOD: 2022- 2030) • Overactive bladder treatment market-size, growth, forecast, by value • by drug analysis : Oxybutynin, Tolterodine, Trospio, Solifenacin, Mirabegron, others • Analysis by therapy: BOTOX, NMS therapy, PTNS.
United States, Canada, Mexico, India, China, Japan, Germany, France, Italy, Spain (ACTUAL PERIOD: 2014-2021, FORECAST PERIOD: 2022- 2030) • Overactive bladder treatment market: scale, growth , Prognosis, by value • Analysis by drug: Oxybutynin, Tolterodine, Trospio, Solinasine, Mirabegron, others • Analysis by therapy: BOTOX, NMS therapy, PTNS. "
The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:
- North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys & Opportunity Outlook
- Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook
Please enter your personal details below
Sanofi S.A., Macleod’s pharmaceuticals Ltd., Apotex, Axonics modulation technologies, Intas Pharmaceuticals, Teva Pharmaceuticals, Laborie, Pfizer Inc., Allergan, Astellas Pharma Inc.